Robert Powers
Internal Medicine · Rogersville, MONPI 1881699072
Payments from drug & device makers
Across 175 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$511
- Otsuka America Pharmaceutical, Inc.$483
- AstraZeneca$473
- Johnson & Johnson$283
- Novartis$202
- Teva Pharmaceuticals USA, Inc.$115
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,255100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 25 | $511 |
| Otsuka America Pharmaceutical, Inc. | 17 | $483 |
| AstraZeneca | 28 | $473 |
| Johnson & Johnson | 20 | $283 |
| Novartis | 10 | $202 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| Collegium Pharmaceutical, Inc. | 7 | $114 |
| Lilly USA, LLC | 6 | $102 |
| AbbVie(2 entities) | 7 | $101 |
| Indivior Inc. | 4 | $87 |
| Abbott | 4 | $82 |
| Novo Nordisk | 4 | $71 |
| Sun Pharmaceutical Industries Inc. | 3 | $67 |
| Pfizer | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Sanara Medtech Inc. | 1 | $57 |
| Boehringer Ingelheim | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Grifols USA, LLC | 2 | $35 |
| GSK | 2 | $35 |
| Bayer | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Amgen | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Biogen | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
How this compares
$3,255 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 440 | $141,860 |
| IngrezzaValbenazine Tosylate | 26 | $95,696 |
| SimponiGolimumab | 13 | $86,084 |
| XifaxanRifaximin | 51 | $81,457 |
| XareltoRivaroxaban | 243 | $80,462 |
| RexultiBrexpiprazole | 59 | $54,658 |
| JardianceEmpagliflozin | 119 | $46,101 |
| MyrbetriqMirabegron | 170 | $42,496 |
| EntrestoSacubitril/Valsartan | 75 | $25,560 |
| FarxigaDapagliflozin Propanediol | 49 | $24,385 |
| OzempicSemaglutide | 24 | $23,883 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 46 | $23,024 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 222 | $21,389 |
| OxycontinOxycodone Hcl | 18 | $19,970 |
| VraylarCariprazine Hcl | 27 | $18,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSimponi, Xarelto, Invokana | $283 | $173,971281 claims |
| PfizerEliquis | $62 | $141,860440 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $511 | $95,69626 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $45 | $75,126188 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $483 | $54,65859 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $42,496170 claims |
| AbbVieVraylar, Linzess | $101 | $37,15663 claims |
| NovartisEntresto | $202 | $25,56075 claims |
| AstraZenecaFarxiga | $473 | $24,38549 claims |
| Novo NordiskOzempic | $71 | $23,88324 claims |
| Lilly USA, LLCTrulicity | $102 | $18,45118 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $114 | $15,64447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Rogersville
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.